Abstract
Cardiometabolic risk comprises a cluster of traditional and emerging factors that are good indicators of a patient’s overall risk for type 2 diabetes and cardiovascular disease. The insulin resistance, a key feature common to obesity and type 2 diabetes, is associated with impaired vascular response and contributes to increased cardiovascular risk. Abnormal vascular insulin signalling induces endothelial dysfunction, the initial step of atherosclerotic process, characterized by attenuated nitric oxide-mediated vasodilatation and atherogenic response. Insulin resistance and endothelial dysfunction are two pathological conditions that can co-exist, even if their cause-effect relationship is not yet clarified. Multiple signaling pathways shared by insulin resistance and endothelial dysfunction include hyperinsulinemia, glucotoxicity, lipotoxicity, and inflammation. These mechanisms selectively impair PI3K-dependent insulin in vascular endothelium harming endothelial balance and strengthening the evidence of the close association between metabolic and cardiovascular disease.
The present review analyzes the close relationship between endothelial dysfunction and insulin resistance and explores the common mechanisms, with clinical considerations and pharmacological strategies.
Keywords: Endothelial dysfunction, insulin resistance, insulin signaling pathways, cardiometabolic risk, cardiovascular disease, type 2 diabetes, glucotoxicity, lipotoxicity, inflammation, hyperinsulinemia
Current Pharmaceutical Design
Title:Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
Volume: 19 Issue: 13
Author(s): Serena Del Turco, Melania Gaggini, Giuseppe Daniele, Giuseppina Basta, Franco Folli, Rosa Sicari and Amalia Gastaldelli
Affiliation:
Keywords: Endothelial dysfunction, insulin resistance, insulin signaling pathways, cardiometabolic risk, cardiovascular disease, type 2 diabetes, glucotoxicity, lipotoxicity, inflammation, hyperinsulinemia
Abstract: Cardiometabolic risk comprises a cluster of traditional and emerging factors that are good indicators of a patient’s overall risk for type 2 diabetes and cardiovascular disease. The insulin resistance, a key feature common to obesity and type 2 diabetes, is associated with impaired vascular response and contributes to increased cardiovascular risk. Abnormal vascular insulin signalling induces endothelial dysfunction, the initial step of atherosclerotic process, characterized by attenuated nitric oxide-mediated vasodilatation and atherogenic response. Insulin resistance and endothelial dysfunction are two pathological conditions that can co-exist, even if their cause-effect relationship is not yet clarified. Multiple signaling pathways shared by insulin resistance and endothelial dysfunction include hyperinsulinemia, glucotoxicity, lipotoxicity, and inflammation. These mechanisms selectively impair PI3K-dependent insulin in vascular endothelium harming endothelial balance and strengthening the evidence of the close association between metabolic and cardiovascular disease.
The present review analyzes the close relationship between endothelial dysfunction and insulin resistance and explores the common mechanisms, with clinical considerations and pharmacological strategies.
Export Options
About this article
Cite this article as:
Del Turco Serena, Gaggini Melania, Daniele Giuseppe, Basta Giuseppina, Folli Franco, Sicari Rosa and Gastaldelli Amalia, Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk, Current Pharmaceutical Design 2013; 19 (13) . https://dx.doi.org/10.2174/1381612811319130010
DOI https://dx.doi.org/10.2174/1381612811319130010 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CYP4 Enzymes As Potential Drug Targets: Focus on Enzyme Multiplicity, Inducers and Inhibitors, and Therapeutic Modulation of 20- Hydroxyeicosatetraenoic Acid (20-HETE) Synthase and Fatty Acid ω- Hydroxylase Activities
Current Topics in Medicinal Chemistry Granulomatous Lung Disease. Disease for Pulmomologists: Diagnosis and Treatment
Current Respiratory Medicine Reviews Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science Recommendations for the Treatment of Hypertension in Patients with DM: Critical Evaluation Based on Clinical Trials
Current Clinical Pharmacology Paliperidone Use in the Elderly
Current Drug Safety How Recent Patents Have Changed our Clinical Approach in Cardio-Thoracic Surgery
Recent Patents on Regenerative Medicine Fractional Flow Reserve: Physiological Basis, Advantages and Limitations, and Potential Gender Differences
Current Cardiology Reviews Disentangling the Intricacies of Migraine: A Review
CNS & Neurological Disorders - Drug Targets Effect of GLP-1 Based Therapies on Diabetic Dyslipidemia
Current Diabetes Reviews "Heart Failure: Meeting the Challenges of Surveillance and Knowledge Translation in Resource-poor Settings"
Current Cardiology Reviews Bioactive Compounds in Diabetic Cardiomyopathy: Current Approaches and Potential Diagnostic and Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Pesticides-induced Cardiovascular Dysfunctions: Prevalence and Associated Mechanisms
Current Hypertension Reviews The Importance of Early Diagnosis and Treatment in Peripheral Arterial Disease: Insights from the PARTNERS and REACH Registries
Current Vascular Pharmacology Is There a Role for Oral Anticoagulant Therapy in Patients with Peripheral Arterial Disease?
Current Drug Targets - Cardiovascular & Hematological Disorders Cellular Membrane Microparticles: Potential Targets of Combinational Therapy for Vascular Disease
Current Vascular Pharmacology The Proteasome as a Therapeutic Target for Lung Fibrosis
Current Enzyme Inhibition The Use of Machine Learning in MicroRNA Diagnostics: Current Perspectives
MicroRNA Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications
Current Gene Therapy Hydroxychloroquine (HCQ) Treatment for Hospitalized Patients with COVID- 19
Infectious Disorders - Drug Targets Editorial (Hot Topic: Matrix Metalloproteinases: Drug Targets in Cardiovascular Diseases)
Current Drug Targets